Study of ABO2102 in KRAS-Mutated Solid Tumors

NCT07455617 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

101

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced / Metastatic Solid Tumor

Interventions

DRUG: ABO2102 Injection
DRUG: Sintilimab injection

Sponsor

Suzhou Abogen Biosciences Co., Ltd.

Collaborators

[object Object]